Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011117653 - DISULFIDE STABILIZED DVD-LG MOLECULES

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A binding protein comprising:

a polypeptide heavy chain comprising:

VH!-(Xj)n-VH2-CH (X2)y

wherein VR\ is a first variable domain, VH2 is a second variable domain, CH is a constant domain, X\ represents an amino acid or peptide, X2 represents an Fc region, n is

0 or 1 and y is independently 1 or 2, and

a polypeptide light chain comprising:


wherein VL] is a first variable domain, VL2 is a second variable domain, C is a constant domain, X\ represents an amino acid or peptide and n is 0 or 1,

wherein the heavy chain and light chain are aligned such that VHi and VLi form a first binding domain, and VH2 and VL2 form a second binding domain and wherein:

there is a disulfide bond between VHi and VL^ and/or

there is a disulfide bond between VH2 and VL2.

2. A binding protein according to claim 1 where the disulfide bond is present between V¾ and VLi.

3. A binding protein according to claim 1 or 2 wherein the disulfide bond is present between VH2 and VL2.

4. A binding protein according to any one of claims 1 to 3, wherein the CH of the heavy chain is linked to the C of the light chain by a disulfide bond.

5. A binding protein according to any one of claims claim 1-4, wherein the peptide Xi is an albumin binding peptide.

6. A pharmaceutically acceptable composition comprising a binding protein as defined in any one of claims 1 to 5.

7. A method of treatment comprising a therapeutically effect amount of a binding protein as defined in any one of claims 1 to 5 or a pharmaceutically acceptable composition according to claim 6.

8. A binding protein as defined in any one of claims 1 to 5 or a pharmaceutically acceptable composition according to claim 6 for use in treatment.

9. Use of a binding protein as defined in any one of claims 1 to 5 or a

pharmaceutically acceptable composition according to claim 6, in the manufacture of a medicament.